1.62
+1.89%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pila Pharma
Its shares trade on Nasdaq Stockholm under the ticker PILA.ST. It has been listed since 15 July 2021. In the fiscal year to 31 December 2025, it reported revenue of SEK 1.1m and a net loss of SEK 16.9m. At that date it held total assets of SEK 16.2m and shareholders' equity of SEK 14.8m.
Pila Pharma AB engages in conducting research and experimental pharmaceutical development. The company is headquartered in Malmo, Skane. The company went IPO on 2021-07-15. The firm conducts clinical tests in phase 2 with drugs against type 2 diabetes. The target product is a tablet that is taken orally in an early stage of diabetes to restore the body's insulin production and thereby reduce the patient's blood sugar level. PILA PHARMA's patent-protected product candidate is called XEN-D0501 and is a TRPV1 antagonist, a novel type of oral anti-diabetic agent for treatment of type 2 diabetes. Pila Pharma AB has completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes. In addition, the product is expected to have fewer unwanted side effects than alternative forms of treatment.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 15 Jul 2021
- Website
- pilapharma.com ↗
Leadership
Pay as last reported
- Dorte Xenia Gram, DVM, PhDChief Executive Officer & Director, since 2014
- Lars Bukhave Rasmussen, DVMChief Operating Officer, since 2020
- Elna Lembrér à ström, CPAChief Financial Officer, since 2022
- Gunnar WredeInvestor Relations Contact
- Fredrik Franz Johan Buch, MD, PhDChairman, since 2016
- Dorte Xenia Gram, DVM, PhDChief Executive Officer & Director, since 2014
- Gudmund Tyge KorsgaardIndependent Director, since 2019
- Lene AndersenIndependent Director, since 2016
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pila Pharma AB's XEN-D0501 is a patent-protected TRPV1 antagonist for type 2 diabetes treatment.
- Pila Pharma AB completed two phase 2a clinical trials PP-CT01 and PP-CT02 with positive results.
- Pila Pharma AB's product is expected to have fewer side effects than alternative treatments for type 2 diabetes.
Weaknesses
- Pila Pharma AB's clinical trials are still in phase 2 for XEN-D0501 development.
- Pila Pharma AB has no commercialized products yet as it is in early development stages.
- Pila Pharma AB's business is limited to type 2 diabetes treatment with XEN-D0501.
Opportunities
- Pila Pharma AB can expand its product portfolio beyond type 2 diabetes treatments.
- Pila Pharma AB can seek partnerships for further clinical trials and development.
- Pila Pharma AB can target global markets for diabetes treatment solutions.
Threats
- Pila Pharma AB faces competition from established pharmaceutical companies in diabetes treatment.
- Pila Pharma AB's development could be delayed by regulatory approvals for XEN-D0501.
- Pila Pharma AB's clinical trial results might not meet expectations for phase 3 trials.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.